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other bleedings (n = 6); stroke during treat‑
ment with OACs or non–vitamin K antagonist 
oral anticoagulants (NOACs; n = 5); and other 
absolute contraindications to OAC or NOACs 
(n = 3). The most common LAA morphology was 
broccoli (n = 22), chicken ‑wing (n = 7), wind‑
sock (n = 7), and other (n = 3).
All LAA closure procedures were done under 
general anesthesia with vascular access from 
the femoral vein. Transseptal puncture was un‑
dertaken under transesophageal echocardiogra‑
phy (TEE) guidance. Next, the Watchman True 
Seal access sheath was advanced over a stiff 
guidewire into the left upper pulmonary vein 
and then repositioned to the LAA over a 6F pig‑
tail catheter. The morphology of LAA was ana‑
lyzed on TEE and angiography for proper de‑
vice selection. The Watchman delivery system 
was prepared and flushed, inserted into the ac‑
cess sheath, and advanced under fluoroscop‑
ic guidance. The device was then deployed into 
the LAA, first forming a “ball” and then using 
one of the following techniques: 1) unsheathe 
method (like with Watchman 2.5); 2) advance‑
ment method; or 3) a combination of both meth‑
ods. A 10‑second push forward on the distal knob 
maneuver was then carried out, which helped 
better engage fixation barbs and conform the im‑
plant to LAA walls. The proper position of the 
device was confirmed by TEE and fluoroscopy. If 
the position was not optimal, the device could be 
repositioned several times both proximally and 
distally using the “ball technique.” The standard 
PASS criteria (position, anchoring, size, seal) for 
device release were then analyzed. The tug test 
was then carried out to confirm the stability be‑
fore the final device release.
Introduction Convincing data from random‑
ized trials and several meta ‑analyses have shown 
that left atrial appendage (LAA) occlusion could 
be used as an alternative to oral anticoagulation 
(OAC).1‑3 In Europe, based on the current recom‑
mendations of the European Society of Cardiol‑
ogy and Polish Cardiac Society, LAA occlusion 
has emerged as a common procedure for stroke 
prevention in patients with atrial fibrillation 
and contraindications to OAC.4 Despite a high 
success rate and low procedural risk associated 
with the current generation of the Watchman 
device, Watchman 2.5 (Boston Scientific, Marl‑
borough, Massachusetts, United States), a new 
generation of the device has been developed, 
namely, Watchman FLX.5,6
The aim of the study was to analyze data on 
the implantation technique, procedural safety, 
complications, and patient outcomes in a single‑
‑center registry summarizing early experience 
with the new generation of the Watchman FLX 
LAA occluder.
Material and methods During the study, 
Watchman FLX was used as the first ‑choice 
device for all patients scheduled for LAA oc‑
clusion (patients included in the Watchman 
FLX LMR and Watchman FLXibility registries). 
The study group (the second largest in Europe) 
included 38 patients (24 men and 14 women) 
at a mean (SD) age of 70.4 (7.5) years. The mean 
(SD) CHA2DS2VASc and HAS ‑BLED scores were 
4.7 (1.4) and 3.5 (0.9), respectively. Previous 
ischemic stroke or transient ischemic attack 
was reported in 15 patients. Indications for LAA 
closure were as follows: gastrointestinal bleed‑
ing (n = 15); intracranial hemorrhage (n = 9); 
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adverse events, including stroke or severe bleed‑
ing. The position of the device was unchanged 
in all patients. We did not observe any throm‑
bi on the device. Leaks around the device (less 
than 3 mm) were noted in 2 patients.
Watchman FLX is the new generation of the 
LAA closure system, available in Europe since 
March 2019. The device has several new features 
when compared with the current generation of 
Watchman 2.5 but also with the previous gener‑
ation of Watchman FLX, which was withdrawn 
from the market by Boston Scientific at the end 
of March 2016 due to a higher device emboli‑
zation rate (3.8%) than initially predicted (al‑
though our own observations were quite sat‑
isfactory even with the previous generation).7
The new Watchman FLX device has been sig‑
nificantly redesigned, although the key benefits 
of its previous version were maintained. The de‑
vice comes in 5 sizes (20 mm, 24 mm, 27 mm, 
31 mm, and 35 mm) for LAA ostia measuring 
from 14 mm to 31.5 mm. Therefore, compared 
with the current generation of Watchman 2.5, 
both smaller and larger LAA ostia can be treat‑
ed. Due to the reduced device length, implan‑
tation even in shallower LAA anatomies is now 
possible (a minimum required depth is only 50% 
of the device size). Watchman FLX has the ni‑
tinol 18‑strut frame structure (10‑strut frame 
in Watchman 2.5), with self ‑expanding proper‑
ties. It not only provides more contact points of 
the device to the LAA ostium but also expands 
radially to maintain a proper position in the LAA. 
Permeable polyester fabric (extended more dis‑
tally than in Watchman 2.5) covers the part of 
the device facing the left atrium. Closed distal 
end with a fluoroscopic marker is atraumatic and 
enhances procedural guidance. Eighteen “J” fix‑
ation anchors in 2 rows (10 anchors in one row 
All patients were included in the Watchman 
FLX LMR and Watchman FLXibility registries. 
The study was approved by a local ethics com‑
mittee. Prior to inclusion, all patients received 
detailed information on the risks and benefits 
of the procedure and signed informed consent.
Results and discussion The LAA closure pro‑
cedure was successful in all 38 patients, without 
the need for intraprocedural changes of the de‑
vice size in all except 1 patient (1.026 devices per 
patient). None of the patients had gaps around 
the device of more than 5 mm (there were gaps 
of 1–3 mm in only 3 patients). The first posi‑
tion of the device was appropriate in 17 patients 
(44.7%). Partial recapture (1–5 per patient) was 
necessary in 21 patients (55.3%): 13 of the 18 
patients (72.2%) during initial experience with 
the device and 8 of the 18 patients (44.4%) in 
the second cohort of patients. The combined 
ball technique of implantation was used in all 
38 patients (100%).
The mean (SD) final maximum diameter of 
the implanted Watchman FLX device was 22.2 
(4.8) mm, with the mean (SD) compression of 
21.1% (4.2%). The mean (SD) procedure time 
was 27 (9) minutes (min–max, 15–54 minutes). 
The distribution of Watchman FLX sizes used 
during the study was as follows: 20 mm (n = 0), 
24 mm (n = 12), 27 mm (n = 13), 31 mm (n = 9), 
and 35 mm (n = 4). No cases of device emboli‑
zation, pericardial effusion, or periprocedur‑
al stroke were observed in our cohort. A total 
of 33 patients were switched to dual antiplate‑
let therapy after LAA occlusion, and 5 patients 
remained on OACs (the group with stroke on 
OAC or NOACs).
Three ‑month follow ‑up data are so far avail‑
able for 27 patients. There were no serious 
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 FIGURE 1 Key feature changes of Watchman FLX in comparison with the previous Watchman 2.5 device: an 18‑strut frame vs 10 
struts for Watchman 2.5, closed distal end with a fluoroscopic marker, reduced device length, 2 rows of the “J” shape anchors (9 in 
each row), and more permeable polyester fabric that extends down to the distal row of the anchors.
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in Watchman 2.5) are located more distally than 
in Watchman 2.5 and facilitate device stabiliza‑
tion in various LAA anatomies. Due to the intra‑
‑LAA placement, the contact of the device with 
the left atrial wall is reduced and potential in‑
terference with the left upper pulmonary vein 
and mitral valve is minimized. The new Watch‑
man FLX device can be recaptured several times 
into the access sheath and repositioned either 
proximally, as the current generation of the de‑
vice, or advanced distally before the final re‑
lease due to the atraumatic closed distal end and 
the use of the new ball technique, which helps 
position the device properly and safely. Thanks 
to the optimized frame shape, the delivery and 
recapture of the device is smoother and easier 
than with Watchman 2.5. The new version of 
Watchman FLX is preloaded in the novel deliv‑
ery system—Watchman True Seal (Boston Sci‑
entific) (14F outer diameter compatible with all 
FLX device sizes). It comes in 3 curve configura‑
tions—single, double, and anterior—for differ‑
ent LAA anatomies. The key feature changes of 
Watchman FLX in comparison with Watchman 
2.5 are presented in FIGURE 1.
In conclusion, periprocedural and short ‑term 
follow ‑up data from the Polish single ‑center 
registry seem to suggest that the new Watch‑
man FLX occluder is safe and highly effective 
in LAA closure. However, the performance and 
safety of the device, although very promising, 
should be confirmed in a larger series of pa‑
tients, with the involvement of other centers 
and operators.
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